|
| Press Releases |
|
 |
|
| Friday, January 10, 2020 |
|
|
SinoMab Granted the "Most Popular Newly Listed Company" Award |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Group has won the title of the "Most Popular Newly Listed Company" at the 4th Hong Kong Golden Stocks Awards held in Shenzhen. more info >> |
|
| Wednesday, November 20, 2019 |
|
|
类风湿关节炎治疗市场蓝海潜力巨大 中国抗体公布在研药物SM03类风湿关节炎III期临床试验最新进展 |
| 中国抗体制药有限公司（「中国抗体」或「公司」，连同其附属公司，统称「集团」；股份代号：3681.HK），专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司，欣然宣布其旗舰在研药物SM03类风湿关节炎III期临床试验最新进展。 more info >> |
|
|
類風濕關節炎治療市場藍海潛力巨大 中國抗體公佈在研藥物SM03類風濕關節炎III期臨床試驗最新進展 |
| 中國抗體製藥有限公司（「中國抗體」或「公司」,連同其附屬公司，統稱「集團」；股份代號：3681.HK），專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司，欣然宣佈其旗艦在研藥物SM03類風濕關節炎III期臨床試驗最新進展。 more info >> |
|
|
Great Potential in RA Therapeutic Market, Sinomab Announces Latest Progress of its Drug Candidate SM03 Phase III Clinical Trial for the Treatment RA |
| SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce its latest progress of SM03 phase III clinical trial for the treatment rheumatoid arthritis. more info >> |
|
| Monday, November 11, 2019 |
|
|
中国抗体（3681.HK）：商业化进程未来可期 |
| 2018年港交所设立新规，允许未盈利公司在香港主板上市，由此揭开了内地生物科技公司赴港上市热潮的序幕。 more info >> |
|
|
中國抗體（3681.HK）：商業化進程未來可期 |
| 2018年港交所設立新規，允許未盈利公司在香港主板上市，由此揭開了內地生物科技公司赴港上市熱潮的序幕。 more info >> |
|
| Wednesday, October 30, 2019 |
|
|
中国抗体制药宣布于港交所主板上市计划 |
| 中国抗体制药有限公司（「中国抗体制药」或「公司」连同其附属公司，统称「集团」；股份代号：3681.HK），专门研究、发展、制造及商业化免疫性疾病疗法且主要研制以单克隆抗体为基础的生物药的香港生物制药公司，今天宣布于香港联合交易所有限公司（「联交所」）主板上市计划。 more info >> |
|
|
中國抗體製藥宣佈於港交所主板上市計劃 |
| 中國抗體製藥有限公司（「中國抗體製藥」或「公司」連同其附屬公司，統稱「集團」；股份代號：3681.HK），專門研究、發展、製造及商業化免疫性疾病療法且主要研製以單克隆抗體為基礎的生物藥的香港生物製藥公司，今天宣佈於香港聯合交易所有限公司（「聯交所」）主板上市計劃。 more info >> |
|
|
SinoMab BioScience Announces Proposed Listing on the Main Board of SEHK |
| SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
亨利加集團舉辦更名誌慶暨香港交易所中午開市儀式
Dec 23, 2024 18:31 HKT/SGT
|
|
|
亨利加集团举办更名志庆暨香港交易所中午开市仪式
Dec 23, 2024 18:18 HKT/SGT
|
|
|
Singapore's most anticipated skyhigh destination C.O.T.U officially opens in iconic Marina Bay this holiday season
Dec 23, 2024 17:10: JST
|
|
|
Nakornthon Hospital PCL (SET: NKT) in First Trading Day on SET
Dec 23, 2024 17:00: JST
|
|
|
日産自動車・Honda・三菱自動車、3社協業形態の検討に関する覚書を締結
Dec 23, 2024 17:00: JST
|
|
|
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 23, 2024 17:22 JST
|
|
|
Singapore's most anticipated skyhigh destination C.O.T.U officially opens in iconic Marina Bay this holiday season
Dec 23, 2024 16:10 HKT/SGT
|
|
|
Nakornthon Hospital PCL (SET: NKT) in First Trading Day on SET
Dec 23, 2024 16:00 HKT/SGT
|
|
|
Feel the Magic of Snowfall at Spritzer EcoPark's Festive Wonder Carnival 2024
Dec 23, 2024 16:00 HKT/SGT
|
|
|
Fujitsu drives chemical industry logistics DX with participation in joint logistics demonstration
Dec 23, 2024 13:30 JST
|
|
|
広汽Hondaの開発区新エネルギー車工場が稼働開始
Dec 23, 2024 11:30: JST
|
|
|
吳佩慈男友紀曉波發聲明 否認參與緬甸「恒升園區」
Dec 23, 2024 11:29 HKT/SGT
|
|
|
吴佩慈男友纪晓波发声明 否认参与缅甸「恒升园区」
Dec 23, 2024 11:27 HKT/SGT
|
|
|
Seamless HDB Renovations: How 2 Design Combines Expertise with In-House Solutions
Dec 23, 2024 11:00: JST
|
|
|
富士通など、モダナイゼーションに特化したファイナンスサービスを提供開始
Dec 23, 2024 10:30: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
